Shintaro Kato

Title: Shintaro Kato: Innovator in Cardiovascular Risk Prediction

Introduction

Shintaro Kato is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of cardiovascular health through his innovative methods for predicting cardiovascular risk events. His work is particularly relevant for patients suffering from coronary heart disease.

Latest Patents

Shintaro Kato holds a patent titled "Cardiovascular risk event prediction and uses thereof." This patent encompasses methods and computer methods used to assess an individual for the prediction of the risk of developing a cardiovascular event over a 1 to 5 year period. The methods utilize at least two biomarkers selected from a list that includes MMP12, angiopoietin-2, complement C7, cardiac troponin I, angiopoietin-related protein 4, CCL18/PARC, alpha-1-antichymotrypsin complex, GDF11, and alpha-2-antiplasmin, or GDF11 in combination with FSTL3. This innovative approach is particularly useful in predicting cardiovascular events in patients with coronary heart disease.

Career Highlights

Shintaro Kato is associated with Somalogic, Incorporated, where he continues to advance research in the field of cardiovascular health. His work has garnered attention for its potential to improve patient outcomes through early risk assessment.

Collaborations

Shintaro has collaborated with notable colleagues, including David Sterling and Edward N Brody. These partnerships have contributed to the development and refinement of his innovative methods.

Conclusion

Shintaro Kato's contributions to cardiovascular risk prediction represent a significant advancement in medical technology. His innovative methods have the potential to greatly enhance patient care and outcomes in the field of cardiovascular health.